Menu
Search
|

Menu

Close
X

InVivo Therapeutics Holdings Corp NVIV.OQ (NASDAQ Stock Exchange Global Market)

0.47 USD
-- (--)
As of Feb 22
chart
Previous Close 0.47
Open --
Volume --
3m Avg Volume 38,950
Today’s High --
Today’s Low --
52 Week High 4.55
52 Week Low 0.45
Shares Outstanding (mil) 32.18
Market Capitalization (mil) 53.11
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.396
FY16
-0.761
FY15
-1.288
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
2.80
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
5.62
16.52
LT Debt to Equity (MRQ)
vs sector
3.32
12.22
Return on Investment (TTM)
vs sector
-83.17
14.43
Return on Equity (TTM)
vs sector
-86.11
16.13

EXECUTIVE LEADERSHIP

Ann Merrifield
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Richard Toselli
President, Acting Chief Executive Officer and Chief Medical Officer, Director, Since 2018
Salary: --
Bonus: --
Christopher McNulty
Principal Financial Officer and Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Melanie Morel-Ferris
Senior Director, Finance and Controller, Since 2017
Salary: --
Bonus: --
Tamara Joseph
Senior Vice President, Chief Compliance Officer, General Counsel, Since 2014
Salary: $133,333.00
Bonus: $37,800.00

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

1 Kendall Sq
CAMBRIDGE   MA   02139-1562

Phone: +1617.8635524

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

SPONSORED STORIES